Litton JK, Scoggins ME, Hess KR, et al. - Researchers examined patients with a known germline BRCA pathogenic variant (gBRCA-positive) and operable breast cancer for the pathologic response of talazoparib alone for 6 months. Twenty patients who had 1 cm or larger invasive tumor and gBRCA-positive disease were eligible for inclusion. They observed a substantial residual cancer burden-0 (pathologic complete response) rate in correlation with neoadjuvant single-agent oral talazoparib once per day for 6 months without chemotherapy; this was observed with manageable toxicity. Findings revealed substantive pathologic response to single-agent talazoparib that justifies the larger, ongoing neoadjuvant trial.